Group 1 - The core point of the article indicates that BluFan Medical (002382) is expected to trigger a downward adjustment of its convertible bond conversion price due to its stock price being below 85% of the current conversion price for 10 consecutive trading days [1][3] - As of October 14, 2025, BluFan Medical's stock closed at 5.6 yuan, reflecting a 1.45% increase with a trading volume of 92,800 shares and a transaction amount of 51.79 million yuan [1] - The main capital flow on October 14 shows a net inflow of 2.785 million yuan from institutional investors, while retail investors experienced a net outflow of 729,700 yuan [1][3] Group 2 - The current conversion price for the convertible bond is 10.50 yuan per share, and if the adjustment condition is triggered, the company will hold a board meeting to discuss whether to revise the conversion price [1] - Historical adjustments of the conversion price have occurred multiple times, with the latest being 10.50 yuan per share as of September 23, 2025, down from previous prices [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002382 证券简称：蓝帆医疗 公告编号：2025-083债券代码：128108 债券简称：蓝帆转债 蓝帆医疗股份有限公司 关于预计触发可转债转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、证券代码：002382，证券简称：蓝帆医疗 2、债券代码：128108，债券简称：蓝帆转债 3、转股价格：人民币10.50元/股 4、转股时间：2020年12月3日至2026年5月27日 5、截至2025年10月14日，蓝帆医疗股份有限公司（以下简称"公司"）股票已有10个交易日的收盘价低 于当期转股价格的85%，预计触发"蓝帆转债"转股价格向下修正条件。若触发条件，公司将于触发条件 当日召开董事会审议决定是否修正转股价格，并及时履行信息披露义务。 一、可转债发行上市基本情况 （一）可转债发行情况 经中国证券监督管理委员会"证监许可〔2020〕710号"文核准，公司于2020年5月28日公开发行了 3,144.04万张可转换公司债券（以下简称"可转债"），每张面值 ...

证券之星消息，截至2025年10月14日收盘，蓝帆医疗(002382)报收于5.6元，上涨1.45%，换手率 0.93%，成交量9.28万手，成交额5179.09万元。 10月14日的资金流向数据方面，主力资金净流入278.5万元，占总成交额5.38%，游资资金净流出205.53 万元，占总成交额3.97%，散户资金净流出72.97万元，占总成交额1.41%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净流入 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-14 | 5.60 | 1.45% | 278.50万 | 5.38% | -205.53万 | -3.97% | -72.97万 | -1.41% | | 2025-10-13 | | 5.52 -1.60% | -791.06万 | -15.15% | 380.38万 | 7.29% | 410.68万 | 7.87% | | 2025-10-10 | | 5.61 0. ...

Core Viewpoint - Bluefan Medical announced that as of October 14, 2025, its stock has closed below 85% of the current conversion price for 10 trading days, which is expected to trigger the downward adjustment condition for "Bluefan Convertible Bonds" [2] Summary by Sections - **Stock Performance** - The company's stock has been underperforming, closing below the specified threshold for 10 consecutive trading days [2] - **Convertible Bonds** - The potential triggering of the downward adjustment condition for the conversion price of the convertible bonds is highlighted, indicating a possible change in the financial terms for bondholders [2] - **Board Meeting** - Upon triggering the condition, the company will convene a board meeting on the same day to decide whether to adjust the conversion price and will fulfill its information disclosure obligations promptly [2]

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-083 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于预计触发可转债转股价格向下修正条件 的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1、证券代码：002382，证券简称：蓝帆医疗 2、债券代码：128108，债券简称：蓝帆转债 3、转股价格：人民币 10.50 元/股 4、转股时间：2020 年 12 月 3 日至 2026 年 5 月 27 日 1、公司于 2021 年 5 月 17 日召开第五届董事会第十五次会议，于 2021 年 6 月 8 日召开 2020 年年度股东大会，审议通过了《关于重大资产重组标的业绩补偿方案的议 案》以及《关于提请股东大会授权公司董事会全权办理重大资产重组标的业绩补偿后 续事项的议案》，同意公司分别以 1 元总价回购注销业绩承诺方淄博蓝帆投资有限公司 持有的公司 23,361,227 股股份、业绩承诺方北京信聿投资中心（有限合伙）持有的公 ...

Group 1 - The stock price of Bluestar Medical (002382) closed at 5.61 yuan on October 10, 2025, with a slight increase of 0.18% and a turnover rate of 0.75% [1] - The trading volume was 75,200 shares, resulting in a total transaction amount of 42.2481 million yuan [1] - On October 10, the net outflow of main funds was 8.6763 million yuan, while retail investors saw a net inflow of 7.6072 million yuan [3] Group 2 - In the third quarter of 2025, the convertible bonds of Bluestar Medical saw a reduction of 30,000 yuan (300 bonds) with a total conversion of 2,633 shares [1][3] - The remaining balance of convertible bonds as of September 30, 2025, was 1,520,439,200 yuan (15,204,392 bonds) [1][3] - The total share capital of the company increased from 1,007,129,466 shares to 1,007,132,099 shares, with an increase of 2,633 shares in the unrestricted circulating shares [1]

Core Insights - Zhengzhou is positioning itself as a key player in the modern industrial system, focusing on high-quality development and the creation of new competitive advantages in response to technological revolutions and industrial transformations [5][6]. Industrial Development - Zhengzhou has seen a cumulative growth of 38.1% in industrial added value since the 14th Five-Year Plan, with total industrial output surpassing 1.9 trillion yuan [6]. - The city is enhancing traditional industries through modernization, with significant advancements in equipment manufacturing, particularly in shield tunneling machines, which have set records in size and capability [7][8]. Emerging Industries - Strategic emerging industries are becoming vital for high-quality development, with Zhengzhou's electronic information sector, led by companies like Foxconn and Super Fusion, achieving substantial growth [12][15]. - Super Fusion's revenue has increased from over 10 billion yuan in 2022 to over 28 billion yuan in 2023, with projections exceeding 40 billion yuan in 2024 [14]. Future Industries - Zhengzhou is actively developing future industries, including artificial intelligence, quantum technology, and low-altitude economy, with initiatives like the establishment of the "Quantum Valley" and the promotion of low-altitude economic zones [19][25][26]. - The city has created several national and provincial pilot zones for future industries, enhancing its reputation as a hub for innovation and technology [19]. Key Achievements - Zhengzhou has become the largest production base for Apple smartphones and intelligent connected buses, as well as the leading producer of gas sensors and superhard materials in China [11]. - The city is also home to significant automotive manufacturing, with companies like BYD and SAIC producing over 1 million new energy vehicles annually [17][18].

Core Viewpoint - Bluefan Medical (002382) has experienced a decline in stock price and financial performance, with significant net outflows from major funds, indicating potential challenges in the market [1][2]. Financial Performance - As of the latest report, Bluefan Medical's total revenue for the first half of 2025 was 2.781 billion yuan, a year-on-year decrease of 7.49% [2]. - The company reported a net profit of -135 million yuan, which is an increase of 15.88% year-on-year, indicating worsening profitability despite the increase in losses [2]. - The second quarter of 2025 saw a single-quarter revenue of 1.303 billion yuan, down 16.0% year-on-year, and a net profit of -212 million yuan, a significant decline of 245.53% year-on-year [2]. Market Position - Bluefan Medical's total market capitalization is 5.64 billion yuan, significantly lower than the industry average of 12.177 billion yuan, ranking 63rd out of 123 companies in the medical device sector [2]. - The company's net assets stand at 9.905 billion yuan, which is above the industry average of 3.889 billion yuan, ranking 7th in the industry [2]. - The price-to-earnings ratio (P/E) is -20.92, compared to the industry average of 67.16, indicating a lack of profitability [2]. Profitability Metrics - Bluefan Medical's gross margin is 14.34%, significantly lower than the industry average of 51.85%, ranking 120th in the industry [2]. - The net profit margin is -5.14%, compared to the industry average of 10.39%, ranking 106th [2]. - Return on equity (ROE) is -1.66%, while the industry average is 1.8%, ranking 112th [2]. Fund Flow Analysis - On October 9, 2025, Bluefan Medical's stock closed at 5.6 yuan, down 0.18%, with a turnover rate of 0.79% and a trading volume of 79,200 hands, amounting to a total transaction value of 44.1552 million yuan [1]. - The net outflow of major funds on the same day was 8.566 million yuan, accounting for 19.4% of the total transaction value, while retail investors saw a net inflow of 4.7937 million yuan, representing 10.86% of the total [1].

（编辑 袁冠琳） 证券日报网讯 蓝帆医疗10月9日在互动平台回答投资者提问时表示，公司参股投资的同心医疗于2025年 6月底完成上市前融资，2025年7月已重启IPO。随着科创板第五套标准重启，其上市进程有望加速。当 然，其上市进程也受宏观经济、监管政策、市场环境及企业自身经营状况等多重因素影响，存在不确定 性。公司将持续关注同心医疗上市进度，具体以同心医疗公司公开披露信息为准。 ...

Core Viewpoint - The company is actively utilizing AI tools in various areas such as sales management, data platforms, and expense management to reduce costs and improve efficiency [2] Group 1 - The company is focusing on the development of cutting-edge technologies in the field of artificial intelligence [2] - The company is particularly interested in applications related to its business, especially in the cardiovascular field [2] - The company will disclose relevant information in accordance with the requirements for listed companies at the appropriate stage [2]